aliskiren / hydrochlorothiazide
The marketing authorisation for Sprimeo HCT has been withdrawn at the request of the marketing-authorisation holder.
Sprimeo HCT : EPAR - Summary for the public (PDF/258.69 KB)
First published: 07/09/2011
Last updated: 28/08/2012
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Novartis Europharm Ltd.
|Date of issue of marketing authorisation valid throughout the European Union||
06/07/2012 Sprimeo HCT - EMEA/H/C/002421 - -
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Agents acting on the renin-angiotensin system
Treatment of essential hypertension in adults.
Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.
Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.